XXVII Конгресс Международного общества по тромбозу и гемостазу
https://doi.org/10.14412/1996-7012-2020-1-118-124
Аннотация
Об авторе
Н. В. СередавкинаРоссия
115522, Москва, Каширское шоссе, 34А
Литература
1. Medcalf R. Message from the ISTH 2019 Congress President. ISTH 2019 Final program. 2019. P. 4-5.
2. McLintock C. Message from the ISTH President. ISTH 2019 Final program. 2019. P. 6-7.
3. Moulinet T, Dufrost V, Clerc-Urmes I, et al. Predictive value of thrombocytopenia in antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
4. Sato T, Amengual O, Fujieda Y, et al. IgM antiphospholipid antibodies: long term follow-up ant thrombotic risk. ISTH 2019 Final program. 2019; OC 23.3. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
5. Ohnishi N, Fujieda Y, Kono M, et al. The prothrombin/MHC class II complex on procoagulant cells as the novel immune target for pathogenic antiphospholipid syndrome. ISTH 2019 Final program. 2019; OC 23.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497
6. Dufrost V, Reshetnyak T, Satybaldyeva M, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data metaanalysis. ISTH 2019 Final program. 2019; OC 23.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
7. Yin D, Chayoua W, De Laat B, et al. Detection of anti-domain I antibodies enables the identification of high-risk antiphospholipid syndrome patients: results of a multicenter study. ISTH 2019 Final program. 2019; OC 23.2. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
8. Zuily S. What is the association between antiphospholipid antibodies and disseminated intravascular coagulation during pregnancy or postpartum period? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
9. Griffin J. The multiple function of protein C and its potential as a therapeutic target. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
10. Brandao L. Clinical presentation and diagnosis of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
11. Monagle P. Acute- and long-term management of protein C deficiency. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
12. Siegal DM. Timing and management of patients needing urganr and emergent procedures: PAUSE ER Study. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
13. Hendriks SV, Bavalia R, Van Bemmel T, et al. Current practice patterns of outpatient management of acute pulmonary embolism: a post-hoc analysis of the year study. ISTH 2019 Final program. 2019; OC 14.1. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1 497
14. Van der Wall SJ, Hendriks SV, Huisman MV, Klok FA. Home treatment of acute pulmonary embolism: state of the art in 2018. Curr Opin Pulm Med. 2018;24(5):425-31. doi: 10.1097/MCP.0000000000000512 15. Rodger M. Recurrent VTE on anticoagulant therapy: what next? Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
15. Galkov M, Sidorova M, Kiseleva E, Gorbacheva L. New peptide – agonist of PAR1 demonstrates neuroprotective effect at the photothrombosis – induced damage of mouse brain. ISTH 2019 Final program. 2019; OC 02.5. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
16. Iastrebova E, Konokhova A, Strokotov D, Maltsev V. Role of erythrocyte gas transport function in the destabilization of atherosclerotic plaque. ISTH 2019 Final program. 2019; OC 12.4. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
17. Panteleev M. Hemodynamics: wall shear rate/blood flow values in human and mouse vessels. Proceedings of the ISTH 2019 Congress. 2019; July 6-10; Melbourne, Australia.
18. Shibeko AM, Chopard B, Hoekstra AG, Panteleev MA. Fibrin clot resistance to thrombolytic therapy is controlled by bypassing flow through collateral vessels, clot permeability and PAI-1 level. ISTH 2019 Final program. 2019; OC 17.4. Available from: рttps://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
19. Satybaldyeva MA, Seredavkina NV, Nasonov EL, et al. Dabigatran for failed warfarin treatment in high-risk patients with antiphospholipid syndrome. ISTH 2019 Final program. 2019; PB 1097. Available from: https://academy.isth.org/isth/#!*menu=6*browseby=3*sortby=2*media=1*ce_id=1497
Рецензия
Для цитирования:
Середавкина НВ. XXVII Конгресс Международного общества по тромбозу и гемостазу. Современная ревматология. 2020;14(1):118-124. https://doi.org/10.14412/1996-7012-2020-1-118-124
For citation:
Seredavkina NV. 27th Congress of the International Society on Thrombosis and Hemostasis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(1):118-124. (In Russ.) https://doi.org/10.14412/1996-7012-2020-1-118-124